International Myeloma Working Group Consensus Statement Regarding the Current Status of Allogeneic Stem-Cell Transplantation for Multiple Myeloma

ArticleinJournal of Clinical Oncology 28(29):4521-30 · October 2010with26 Reads
Impact Factor: 18.43 · DOI: 10.1200/JCO.2010.29.7929 · Source: PubMed

    Abstract

    To define consensus statement regarding allogeneic stem-cell transplantation (Allo-SCT) as a treatment option for multiple myeloma (MM) on behalf of International Myeloma Working Group.
    In this review, results from prospective and retrospective studies of Allo-SCT in MM are summarized.
    Although the introduction of reduced-intensity conditioning (RIC) has lowered the high treatment-related mortality associated with myeloablative conditioning, convincing evidence is lacking that Allo-RIC improves the survival compared with autologous stem-cell transplantation.
    New strategies are necessary to make Allo-SCT safer and more effective for patients with MM. Until this is achieved, Allo-RIC in myeloma should only be recommended in the context of clinical trials.